Advice
Following a re-submission
ibritumomab tiuxetan (Zevalin®) is not recommended for use within NHS Scotland for the preparation of a radiopharmaceutical incorporating Yttrium 90 [90Y] for the treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL).
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice57KB (PDF)
Medicine details
- Medicine name:
- ibritumomab tiuxetan (Zevalin)
- SMC ID:
- 171/05
- Indication:
- CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL)
- Pharmaceutical company
- Schering Health Care Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 09 July 2007